Literature DB >> 32888110

Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions.

Omer Karadag1,2, Emine Duran3,4.   

Abstract

Entities:  

Year:  2020        PMID： 32888110     DOI： 10.1007/s11739-020-02481-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  9 in total

1.  Cryoglobulinemia after the era of chronic hepatitis C infection.

Authors:  Gonçalo Boleto; Pascale Ghillani-Dalbin; Lucile Musset; Lucie Biard; Guillaume Mulier; Patrice Cacoub; David Saadoun
Journal:  Semin Arthritis Rheum       Date:  2020-05-26       Impact factor: 5.532

2.  Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).

Authors:  Caterina Vacchi; Marcella Visentini; Laura Gragnani; Paolo Fraticelli; Antonio Tavoni; Davide Filippini; Francesco Saccardo; Gianfranco Lauletta; Stefania Colantuono; Fabiola Atzeni; Pietro Pioltelli; Andreina Manfredi; Milvia Casato; Anna Linda Zignego; Giuseppe Monti; Maurizio Pietrogrande; Massimo Galli; Marco Sebastiani
Journal:  Intern Emerg Med       Date:  2020-06-10       Impact factor: 3.397

Review 3.  Cryoglobulinemia Vasculitis.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; David Saadoun
Journal:  Am J Med       Date:  2015-03-30       Impact factor: 4.965

4.  Cryoglobulinemia; report of two cases with discussion of clinical manifestations, incidence and significance.

Authors:  D P BARR; G G READER; C H WHEELER
Journal:  Ann Intern Med       Date:  1950-01       Impact factor: 25.391

Review 5.  The dilemma of treating hepatitis C virus-associated cryoglobulinemia.

Authors:  Dario Roccatello; Roberta Fenoglio; Savino Sciascia
Journal:  Curr Opin Rheumatol       Date:  2019-09       Impact factor: 5.006

6.  The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

Authors:  László Gulácsi; Valentin Brodszky; Petra Baji; Fanni Rencz; Márta Péntek
Journal:  Adv Ther       Date:  2017-04-10       Impact factor: 3.845

7.  Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome.

Authors:  Anne Claire Desbois; Lucie Biard; Damien Sène; Isabelle Brocheriou; Philippe Rouvier; Bertrand Lioger; Lucile Musset; Sophie Candon; Thierry Zenone; Matthieu Resche-Rigon; Jean-Charles Piette; Neila Benameur; Patrice Cacoub; David Saadoun
Journal:  J Rheumatol       Date:  2019-08-01       Impact factor: 4.666

Review 8.  B-cell-targeted therapy in systemic vasculitis.

Authors:  Lindsay Lally; Robert Spiera
Journal:  Curr Opin Rheumatol       Date:  2016-01       Impact factor: 5.006

9.  Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.

Authors:  Won Park; Ljubinka Božić-Majstorović; Dragana Milakovic; Alfredo Berrocal Kasay; Elias Chalouhi El-Khouri; Fedra Irazoque-Palazuelos; Francisco Fidencio Cons Molina; Pavel Shesternya; Pedro Miranda; Francisco G Medina-Rodriguez; Piotr Wiland; Slawomir Jeka; Jose Chavez-Corrales; Olena Garmish; Thomas Linde; Dmytro Rekalov; Pawel Hrycaj; Andreas Krause; Natalia Fomina; Olena Piura; Mauricio Abello-Banfi; Chang-Hee Suh; Seung Cheol Shim; Sang Joon Lee; Sung Young Lee; Sung Hwan Kim; Dae Hyun Yoo
Journal:  MAbs       Date:  2018-07-16       Impact factor: 5.857
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.